Display options
Cite
Lee KH, Lim YT, Hah JO, et al. Voriconazole plus caspofungin for treatment of invasive fungal infection in children with acute leukemia. Blood Res. 2017;52(3):167-173doi: 10.5045/br.2017.52.3.167.
Lee, K. H., Lim, Y. T., Hah, J. O., Kim, Y. K., Lee, C. H., & Lee, J. M. (2017). Voriconazole plus caspofungin for treatment of invasive fungal infection in children with acute leukemia. Blood research, 52(3), 167-173. https://doi.org/10.5045/br.2017.52.3.167
Lee, Kyu Ho, et al. "Voriconazole plus caspofungin for treatment of invasive fungal infection in children with acute leukemia." Blood research vol. 52,3 (2017): 167-173. doi: https://doi.org/10.5045/br.2017.52.3.167
Lee KH, Lim YT, Hah JO, Kim YK, Lee CH, Lee JM. Voriconazole plus caspofungin for treatment of invasive fungal infection in children with acute leukemia. Blood Res. 2017 Sep;52(3):167-173. doi: 10.5045/br.2017.52.3.167. Epub 2017 Sep 25. PMID: 29043231; PMCID: PMC5641508.
Copy Download .nbib Format: NLM
Share it on

Blood Res. 2017 Sep;52(3):167-173. doi: 10.5045/br.2017.52.3.167. Epub 2017 Sep 25.

Voriconazole plus caspofungin for treatment of invasive fungal infection in children with acute leukemia.

Blood research

Kyu Ho Lee, Young Tae Lim, Jeong Ok Hah, Yu Kyung Kim, Chae Hoon Lee, Jae Min Lee

Affiliations

  1. Department of Pediatrics, College of Medicine, Yeungnam University, Daegu, Korea.
  2. Department of Pediatrics, Daegu Fatima Hospital, Daegu, Korea.
  3. Department of Clinical Pathology, Kyungpook National University School of Medicine, Daegu, Korea.
  4. Department of Laboratory Medicine, College of Medicine, Yeungnam University, Daegu, Korea.

PMID: 29043231 PMCID: PMC5641508 DOI: 10.5045/br.2017.52.3.167

Abstract

BACKGROUND: Invasive fungal infections (IFIs) are a life-threatening problem in immunocompromised patients. Despite timely diagnosis and appropriate antifungal therapy, clinical outcomes of IFIs remain unsatisfactory, necessitating treatment with a combination of antifungal agents. Therefore, childhood leukemic patients treated with voriconazole plus caspofungin were evaluated for the safety and efficacy of the combination antifungal therapy to treat IFIs.

METHODS: In this retrospective study, medical records were retrieved for patients admitted to the Pediatric Department of Yeungnam University Hospital, Daegu, South Korea, between April 2009 and May 2013. Medical records of 22 patients were analyzed.

RESULTS: Of the 22 patients studied, nine (41%) had been diagnosed with probable IFI, and 13 (59%) with possible IFI. All patients, except one, were already receiving antifungal monotherapy for the treatment of neutropenic fever. After a diagnosis of IFI was confirmed, antifungal monotherapy was replaced with combination therapy. The study's overall response rate was 90.9%, with complete responses in 86.3% of the patients. Two patients experienced a side effect of a small increase in liver enzyme levels.

CONCLUSION: Voriconazole plus caspofungin combination therapy is an effective and safe treatment for serious IFI in pediatric patients with acute leukemia.

Keywords: Antifungal agent; Aspergillosis; Caspofungin; Echinocandins; Invasive fungal infections; Voriconazole

Conflict of interest statement

Authors' Disclosures of Potential Conflicts of Interest: No potential conflicts of interest relevant to this article were reported.

References

  1. Clin Infect Dis. 2008 Jun 15;46(12):1813-21 - PubMed
  2. Eur J Haematol. 2014 Jun;92 (6):541-5 - PubMed
  3. Semin Oncol. 2009 Jun;36(3):213-26 - PubMed
  4. Cancer. 2007 Dec 15;110(12 ):2740-6 - PubMed
  5. Lancet Oncol. 2014 Jul;15(8):e327-40 - PubMed
  6. Cancer. 2003 Jul 15;98 (2):292-9 - PubMed
  7. Mycoses. 2014 Jun;57(6):342-50 - PubMed
  8. Int J Antimicrob Agents. 2015 Mar;45(3):283-8 - PubMed
  9. Pediatr Infect Dis J. 2006 Jul;25(7):634-9 - PubMed
  10. Clin Infect Dis. 2015 Mar 1;60(5):713-20 - PubMed
  11. BMC Infect Dis. 2007 Apr 18;7:28 - PubMed
  12. Mycoses. 2008 Mar;51(2):109-16 - PubMed
  13. J Pediatr Hematol Oncol. 2009 Sep;31(9):642-6 - PubMed
  14. Antimicrob Agents Chemother. 2002 Jan;46(1):245-7 - PubMed
  15. Antimicrob Agents Chemother. 2002 Sep;46(9):3039-41 - PubMed
  16. Pediatr Blood Cancer. 2013 Feb;60(2):316-22 - PubMed
  17. Pharmacotherapy. 2016 Oct;36(10 ):1102-1108 - PubMed
  18. Clin Infect Dis. 2007 May 15;44(10):1289-97 - PubMed
  19. Mycoses. 2011 Jan;54 Suppl 1:39-44 - PubMed
  20. Int J Hematol. 2012 Dec;96(6):748-57 - PubMed
  21. J Infect. 2006 Jan;52(1):67-74 - PubMed
  22. Clin Infect Dis. 2008 Sep 1;47(5):674-83 - PubMed
  23. Antimicrob Agents Chemother. 2002 Aug;46(8):2564-8 - PubMed
  24. Antimicrob Agents Chemother. 2006 Apr;50(4):1567-9 - PubMed
  25. J Antimicrob Chemother. 2016 Nov;71(11):3135-3147 - PubMed
  26. Expert Rev Anti Infect Ther. 2013 May;11(5):523-35 - PubMed
  27. Pediatr Blood Cancer. 2013 Jan;60(1):82-7 - PubMed
  28. Pediatr Clin North Am. 2015 Feb;62(1):61-73 - PubMed
  29. Pharmacology. 2005 Dec;75(4):165-78 - PubMed

Publication Types